Clinically Proven Phototherapy

Treat Yourself to
Phototherapy

A safe & effective topical cream for psoriasis & vitiligo — harnessing the sun’s therapeutic UV right from your own home.

100%Response Rate — Vitiligo & Psoriasis
43%Complete Psoriasis Clearance
75%Mean Psoriasis Lesion Clearance
0Serious Adverse Events (All Trials)
CDSCO Approved — India
Cosmetic Registration — LATAM
US Patent No. 10,111,821
Steroid Free
No Injections
Sun-Powered Treatment
About Photocil

What is Photocil?

A topical cream that provides clinically-proven relief to psoriasis and vitiligo symptoms — no lamp, no clinic.

30 min
Average Session Length
Per Week
12 wks
Average Treatment Plan

Monotherapy or Adjuvant — Your Choice

Photocil can be used as a standalone treatment (monotherapy) or in combination with existing medications for psoriasis, vitiligo, or atopic dermatitis. Because it works as a purely mechanical sunscreen-like barrier on the skin surface — allowing only therapeutic NB-UVB wavelengths through — it does not interact with, or enter, the body. It does not affect systemic drugs or biologics. In fact, it may enhance their effectiveness by delivering targeted adjuvant phototherapy simultaneously.

A Smarter Way to Access Phototherapy

Phototherapy has long been an established standard-of-care treatment for psoriasis and vitiligo. Prior to Photocil, it was only available through a UV photo lamp — most commonly administered at a medical clinic.

Photocil cream acts as a precision filter, blocking non-therapeutic solar radiation while selectively allowing the therapeutic NB-UVB wavelengths through to your skin. This gives you the benefits of traditional phototherapy, powered by natural sunlight.

Photocil is steroid free, requires no oral medication and no injections. In clinical trials, patients experienced no side effects.*

*Not available in the U.S. as OTC.

The Science — Dead Sea in a Tube

The Dead Sea (400m below sea level) is famous for healing skin conditions because the extra atmosphere filters out harmful low-UVB wavelengths, leaving only therapeutic 311–313nm NB-UVB. Photocil replicates this effect anywhere on earth — two photostable UV-absorbing molecules (α-Glucosyl Hesperidin & DHHB) form a band-pass filter on the skin surface, blocking erythema-causing wavelengths while selectively transmitting therapeutic NB-UVB.

311–313 nm
Therapeutic NB-UVB action spectrum
<300 nm blocked
Erythema-causing wavelengths filtered
α-GH + DHHB
Two photostable active molecules
Skin-surface only
No systemic absorption

Regulatory Approvals & FDA Listings

US FDA NDC
54841-001-03
Indicated for:
Vitiligo Psoriasis Atopic Dermatitis Chronic Pruritus
CDSCO Approved — India (Photofirst™) Registered Cosmetic — LATAM US Patent No. 10,111,821 Product Monograph

ⓘ US FDA NDC: 54841-001-03 (Applied Biology Inc.). Registered as cosmetic in India (Photofirst™, CDSCO) and LATAM markets. Source: Expert Opinion on Pharmacotherapy, 2014.

Mechanism

How Photocil Works

How Photocil Works for Psoriasis

For Psoriasis

Click to enlarge

How Photocil Works for Vitiligo

For Vitiligo

Click to enlarge

“I live in a small town — there’s no phototherapy clinic nearby, and I simply couldn’t travel to the city three times a week. A dermatologist recommended Photocil and it changed everything. Within 12 weeks I cleared my vitiligo completely at home, in natural sunlight — no steroids, no injections, no clinic visits. Just the cream and the sun.”
— Vitiligo Patient, Maharashtra, India
Clinical Outcomes

Results with Photocil

Real patient before & after results from published clinical trials.

Psoriasis Result
Psoriasis

Before & After

Treatment Time: 12 Weeks

Vitiligo Result
Vitiligo

Before & After

Treatment Time: 9 Weeks

Psoriasis Result
Psoriasis

Before & After

Treatment Time: 12 Weeks

Vitiligo Result
Vitiligo

Before & After

Treatment Time: 11 Weeks

Psoriasis Result
Psoriasis

Before & After

Treatment Time: 12 Weeks

2025 Clinical Data
2025 Clinical Data

Real-World Outcomes

Multicenter India Study

“Photocil is a safe & viable treatment for psoriasis & vitiligo patients. Photocil provides an effective alternative to the photo booth.”
— Prof. Torello Lotti, MD (Chairman of Dermatology, University of Rome, Italy) —
Evidence Base

Published Clinical Studies

Photocil is supported by peer-reviewed published research across vitiligo, psoriasis and atopic dermatitis.

1
Topical cream delivers NB-UVB from sunlight for the treatment of vitiligo
Wang X, McCoy J, Lotti T, Goren A.
Expert Opinion on Pharmacotherapy. 2014 Dec;15(18):2623–2627. doi: 10.1517/14656566.2014.978287
Landmark paper describing the mechanism and clinical efficacy of topical Photocil for vitiligo. Shows how the cream selectively filters solar radiation to deliver therapeutic NB-UVB to lesions, providing a convenient home-based alternative to clinic phototherapy.
2
Double-blind, placebo-controlled clinical study on Photocil phototherapy in vitiligo
Goren A, Salafia A, McCoy J, Lotti T.
Journal of the European Academy of Dermatology and Venereology — Pivotal trial.
15 patients with acrofacial vitiligo. 100% response rate in the Photocil arm following an average of 11 weeks at 3 sessions/week. 28% achieved ≥70% repigmentation, 28% achieved ≥50%. No serious adverse events. Results comparable to traditional NB-UVB and Dead Sea heliotherapy.
3
Topical Band-pass Filter Cream (TBFC)-assisted home-based NB-UVB: A must-know alternative to artificial phototherapy
Sonthalia S.
Journal of Cosmetic Dermatology. 2021 Jul;20(7):2141–2147. doi: 10.1111/jocd.14215
Review article examining home-based NB-UVB using topical band-pass filter cream (Photocil). Discusses clinical rationale, safety profile, and practical implementation as an alternative to clinic-based phototherapy. Characterises Photocil as a "must-know" alternative modality for dermatologists.
4
Photocil for vitiligo: clinical application and case series
Lotti T, Goren A et al.
Dermatologic Therapy — Published case series.
Real-world case series evaluating Photocil across multiple vitiligo subtypes in a clinical setting. Demonstrates consistent repigmentation outcomes and practical applicability in routine dermatology practice.
5
Photocil as adjunct to NB-UVB phototherapy in plaque psoriasis
Goren A, Lotti T, McCoy J.
Published pilot study — psoriasis indication.
Pilot study in plaque psoriasis patients demonstrating favourable PASI improvement. Results consistent with traditional NB-UVB phototherapy literature, supporting broad applicability of Photocil across phototherapy-indicated skin conditions.
6
Multicenter prospective real-world study of Photofirst (Photocil) in Indian dermatology centres Under Peer Review
Multicenter India study group.
Indian Dermatology Online Journal (IDOJ). Manuscript idoj_1078_25
Prospective multicenter real-world study evaluating Photofirst (India brand of Photocil) across Indian dermatology centres. This study will provide the first India-specific clinical evidence base for the product when published.
Simple Protocol

Ease of Use

Treatment with Photocil is easy. Just follow this simple guide.

1

Check for sunny conditions and plan for shortest session time (close to noon).

2

Apply Photocil liberally to affected areas of skin.

3

Cover non-affected skin with clothing, hat, and SPF 30+ sunscreen.

4

Proceed outside.

5

Visit photocil.com/sun or use the Photocil mobile app to begin your session.

6

Expose skin to direct daylight while the Session System tracks time.

7

Photocil Session System notifies you when to end your session.

8

Return inside. That’s it — treatment complete.

Real-World Evidence

Indian Case Studies

Published in Ray-N-Ovation — real-world outcomes from Indian dermatologists using Photofirst™ in clinical practice.

Issue 2 · Sagar, MP
Dr. Sharad & Raghav Gupta
Segmental Vitiligo

14-year-old boy with vitiligo patches on the anterior abdominal wall. Repigmentation observed at Day 30 following 20-min sunlight sessions (winter) with Photofirst™.

Response at 30 days · No prior comorbidities
Download Case Study
Issue 3 · Surat
Dr. Yogesh Bhingradia
Focal Vitiligo — Scalp

57-year-old male with hypopigmented patches on scalp. Previous treatments included Trioxalen and Tacrolimus. Significant scalp repigmentation after 3 months on Photofirst™ 3×/week.

3 months · 3×/week · Combination therapy
Download Case Study
Issue 5 · Jalgaon
Dr. Pradnya P. Jadhav
Pediatric Focal Vitiligo — Eyelid

6-year-old girl with discolored patches on upper eyelid for 3 months. Maternal family history of vitiligo. Used with topical Tacrolimus. Complete repigmentation at 8 weeks.

8 weeks · Complete clearance · Pediatric
Download Case Study
Literature

Download Published Research

Peer-reviewed manuscripts, case studies, and the Photofirst™ product monograph — all available to download.

Topical cream delivers NB-UVB from sunlight for the treatment of vitiligo
Wang X, McCoy J, Lotti T, Goren A.
Expert Opinion on Pharmacotherapy. 2014. DOI: 10.1517/14656566.2014.978287
PDF
Novel topical cream delivers safe and effective sunlight therapy for vitiligo by selectively filtering damaging ultraviolet radiation
Goren A, Salafia A, McCoy J, Keene S, Lotti T.
Dermatologic Therapy. 2014. 100% response rate, 28% achieved ≥70% repigmentation.
PDF
Novel topical cream delivers safe and effective alternative to traditional psoriasis phototherapy
Goren A, Salafia A, McCoy J, Keene S, Lotti T, Petrusevska A.
Dermatologic Therapy. 2014;27:260–263. 43% complete clearance, 75% mean surface area clearance (p<0.00012).
PDF
In vitro evaluation of a novel topical cream for vitiligo and psoriasis that selectively delivers NB-UVB therapy when exposed to sunlight
McCoy J, Goren A, Lotti T.
Dermatologic Therapy. 2014;27:117–120. Foundational in vitro characterisation of α-GH + DHHB band-pass filter formulation.
PDF
Management of chronic pruritus with a UV filtering topical cream
Zanardelli M, Kovacevic M, McCoy J, Wang X, Goren A, Lotti T.
Dermatologic Therapy. 2016;29:101–103. All 7 pruritus patients noted improvement after 3 months.
PDF
Ray-N-Ovation Issue 2 — Segmental Vitiligo
Dr. Sharad Gupta & Dr. Raghav Gupta · Sagar Skin Clinic, Madhya Pradesh
14-year-old male · Repigmentation at Day 30 · 20-min sunlight sessions
PDF
Ray-N-Ovation Issue 3 — Focal Scalp Vitiligo
Dr. Yogesh Bhingradia · Shivani Skin Care & Cosmetic Clinic, Surat
57-year-old male · Significant scalp repigmentation after 3 months · Prior Tacrolimus
PDF
Ray-N-Ovation Issue 5 — Pediatric Eyelid Vitiligo
Dr. Pradnya Pratap Jadhav · Consultant Dermatologist, Jalgaon
6-year-old girl · Complete repigmentation at 8 weeks · Combination with Tacrolimus
PDF

Photofirst™ Product Monograph

Comprehensive prescribing information, clinical data, pharmacology, dosing protocols, safety profile, and regulatory status for Photofirst™ (Photocil®) — intended for healthcare professionals.

Ready to try Photocil?

We can help you find a doctor or distributor in your country.

Get in Touch
Contact

Get in Touch

Reach out to San Pellegrino Cosmetics Pvt. Ltd. — India Licensee & Distributor of Photocil®

San Pellegrino Cosmetics Pvt. Ltd.

India Licensee & Distributor for Photocil® (Photofirst™) · Gurugram, Haryana, India

All enquiries — patients, HCPs, distributors & licensees — are directed to arjunkhurana@spcindia.net
General Enquiriesarjunkhurana@spcindia.net
Medical / HCP Informationarjunkhurana@spcindia.net
India BrandPhotofirst™ — CDSCO Approved, November 2022
Distributed via Eris Lifesciences
IP ReferenceUS Patent No. 10,111,821
Licensed from Caring Brands International (CABR)
Active MarketsIndia, Mexico, Brazil, Colombia, Ecuador, Peru, Dominican Republic, UAE, Saudi Arabia, Egypt, Korea, Philippines, Indonesia, Thailand, Vietnam, Kazakhstan
Regulatory StatusCDSCO Approved (India) • CE-IVDD (Europe) • US Patent 10,111,821
Business Developmentarjunkhurana@spcindia.net
Contact PersonArjun Khurana
Founder & Director, SPC India

Send a Message

Thank you! We’ll be in touch shortly.